| Subject |
The findings of the MoA studies on Fespixon(ON101) under collaboration with TMU and NYCU have been accepted and published by a renown SCI journal, JID Innovations |
- Date of occurrence of the event:2022/06/02
- Company name:ONENESS BIOTECH CO., LTD.
- Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office
- Reciprocal shareholding ratios:NA
- Cause of occurrence:
Fespixon (research code: ON101) is the first-in-class macrophage-regulation new drug which demonstrated clinical superiority in the healing of the diabetic foot ulcers. The in vitro and in vivo data confirmed that Fespixon promotes the healing by decreasing the pro-inflammatory M1 macrophages and increasing the pro-regenerative M2a/M2c macrophages via stimulating adipose-derived progenitor cells to secrete GCSF and CXCL3. The study findings have been submitted to and published by JID Innovations, the open access of JID, a leading dermatological journal.
- Countermeasures:None
- Any other matters that need to be specified:
(1)Two global leading dermatological medical associations, Society for Investigative Dermatology (SID) and European Society for Dermatological Research (ESDR) have established the Journal of Investigative Dermatology (JID) since 1938. JID has been the leading dermatological research journal. The articles on JID is more basic-research-driven and in order to accelerate more researches into treatment and application for medical dermatology, SID and ESDR established JID Innovations, an open-access journal in 2021. The manuscripts for researches into pathology of dermatological disorders and therapeutic approaches will be peer-reviewed by medical dermatologists and key opinion leaders for online publication. JID innovations has not received an impact factor yet as it has not been established for 2 years. However, many influential review articles were already published on this journal. With the meticulous review process, JID Innovations has become an important journal in medical dermatology in Europe and the U.S.
(2)The mechanism of action of Fespixon has been reconfirmed by in vitro and in vivo studies and published on JID Innovations. This is an acknowledgement by the leading dermatological journal on Fespixon’s unique mechanism of action and its scientific evidence. The open access will increase the understanding of the podiatric and dermatological specialists on Fespixon’s first-in-class mechanism in treating chronic ulcers and also raise the global profile of the new drug. It is hoped that this will benefit the global DFU patients.
(3)The article is available online on JID Innovations:
https://www.jidinnovations.org/article/S2667-0267(22)00046-7/fulltext
|
